Effects of age and gender on immunogenicity and reactogenicity of SpikoGen recombinant spike protein vaccine: a post-hoc analysis
Scientific Reports · 2024
DOI: 10.1038/s41598-024-67945-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scientific Reports, 2024. Verfasst von Nassim Anjidani und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical Department, Orchid Pharmed Company, No. 12 Asad Abadi Street, 70th Alley, Tehran, 1969955311, Iran. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, COVID-19 Vaccines, COVID-19, Antibodies, Neutralizing. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
SpikoGen® COVID-19 vaccine is based on the spike protein extracellular domain of the ancestral Wuhan-Hu-1 strain modified by removal of the furin cleavage site and addition of stabilising mutations expressed as a recombinant protein in insect cells. It is formulated with Advax-CpG55.2™ adjuvant to ensure optimal immunogenicity. In this study, data from several SpikoGen® clinical trials was retrospectively analysed to assess for any effect of gender or age on seroconversion, neutralizing antibody levels or the incidence of adverse events. Following the 1st dose, older age was associated with a reduced rate of fatigue (RR 0.97, p < 0.001), headache (RR 0.98, p = 0.034) and myalgia (RR 0.97, p=0.016), following the 2nd dose, the rate of fatigue (RR 0.98, p = 0.017) but following the 3rd dose no effect of age on adverse events was evident. Similarly, following the 1st dose, men reported a 19% lower incidence of fatigue, 36% lower incidence of headache and 28% lower incidence of myalgia when compared to women. Interestingly, there was no relationship between age or gender and serum neutralizing antibody levels, although after each vaccine dose there was a consistent trend to women having a higher seroconversion rate. There was no correlation between neutralizing antibody levels and adverse events. Unlike what is seen with mRNA vaccines, reactogenicity trended lower after each subsequent SpikoGen® dose. Overall, SpikoGen® exhibited positive immunogenicity and low reactogenicity, indicating that a low incidence of adverse events does not equate to poor immunogenicity. SpikoGen® remains a promising protein-based vaccine platform for COVID-19 protection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical Department, Orchid Pharmed Company, No. 12 Asad Abadi Street, 70th Alley, Tehran, 1969955311, Iran.
- Vaxine Pty Ltd, Bedford Park, Adelaide, 5042, Australia.
- Medical Department, Orchid Pharmed Company, No. 12 Asad Abadi Street, 70th Alley, Tehran, 1969955311, Iran. Barati.S@orchidpharmed.com.
Zitieren
APA
Anjidani, N., Shahpari, R., Kafi, H., Petrovsky, N., & Barati, S. (2024). Effects of age and gender on immunogenicity and reactogenicity of SpikoGen recombinant spike protein vaccine: a post-hoc analysis. Scientific Reports. https://doi.org/10.1038/s41598-024-67945-3
Vancouver
Anjidani N, Shahpari R, Kafi H, Petrovsky N, Barati S. Effects of age and gender on immunogenicity and reactogenicity of SpikoGen recombinant spike protein vaccine: a post-hoc analysis. Scientific Reports. 2024. doi:10.1038/s41598-024-67945-3
BibTeX
@article{Anjidani2024,
author = {Anjidani, Nassim and Shahpari, Ramin and Kafi, Hamidreza and Petrovsky, Nikolai and Barati, Saghar},
title = {Effects of age and gender on immunogenicity and reactogenicity of SpikoGen recombinant spike protein vaccine: a post-hoc analysis},
journal = {Scientific Reports},
year = {2024},
doi = {10.1038/s41598-024-67945-3}
}
EUVIMED